Takeda Pharmaceutical (NYSE:TAK) Releases Earnings Results, Beats Expectations By $0.36 EPS

Takeda Pharmaceutical (NYSE:TAK) issued its earnings results on Wednesday. The company reported $0.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.36, Zacks reports. The business had revenue of $28.19 billion for the quarter, compared to analyst estimates of $7.14 billion. Takeda Pharmaceutical had a net margin of 4.31% and a return on equity of 11.23%. Takeda Pharmaceutical updated its FY 2026 guidance to 3.009-3.009 EPS.

Here are the key takeaways from Takeda Pharmaceutical’s conference call:

• Takeda said fiscal 2025 was a strong year for its pipeline, with positive Phase III data for oveporexton, rusfertide and zasocitinib, plus positive pivotal results for TAK-881. Management framed these as setting up multiple near-term launches and a broader late-stage pipeline with significant long-term potential.
• FY2025 core revenue was about JPY 4.5 trillion and core operating profit was JPY 1.17 trillion, with results pressured by Vyvanse generic erosion but supported by disciplined cost control. Core EPS still grew 3.1% at constant currency, and free cash flow remained strong at JPY 684.5 billion.
• The company highlighted three major launches expected within the next 12 months: oveporexton for narcolepsy type 1, rusfertide for polycythemia vera, and zasocitinib for psoriasis. Takeda said all three have priority review status or equivalent momentum and could become future blockbuster brands.
• FY2026 guidance calls for low-single-digit revenue decline and core operating profit down 5% to 8% at constant exchange rates, as Takeda invests heavily in launches and R&D. The company also expects about JPY 170 billion of restructuring costs and roughly 4,500 roles impacted by its transformation program.
• Management said its new transformation program should deliver more than JPY 200 billion of annualized gross savings by FY2028, supporting a return to growth and helping fund future launches. Takeda also plans to increase the annual dividend to JPY 204 per share and continue deleveraging toward a 2x net debt/EBITDA target.

Takeda Pharmaceutical Price Performance

Shares of Takeda Pharmaceutical stock traded down $0.02 on Friday, hitting $16.61. The company had a trading volume of 2,789,063 shares, compared to its average volume of 3,043,384. The company has a market cap of $52.86 billion, a PE ratio of 9.67 and a beta of -0.06. Takeda Pharmaceutical has a 52 week low of $12.99 and a 52 week high of $18.90. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.19 and a quick ratio of 0.65. The business has a 50-day simple moving average of $17.62 and a 200-day simple moving average of $16.41.

Institutional Trading of Takeda Pharmaceutical

A number of large investors have recently added to or reduced their stakes in the business. UBS Group AG lifted its position in shares of Takeda Pharmaceutical by 46.4% in the 3rd quarter. UBS Group AG now owns 5,893,969 shares of the company’s stock valued at $86,288,000 after acquiring an additional 1,869,323 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its position in shares of Takeda Pharmaceutical by 132.1% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 2,828,778 shares of the company’s stock valued at $41,413,000 after acquiring an additional 1,610,088 shares in the last quarter. Qube Research & Technologies Ltd lifted its position in shares of Takeda Pharmaceutical by 407.9% in the 3rd quarter. Qube Research & Technologies Ltd now owns 1,775,845 shares of the company’s stock valued at $25,998,000 after acquiring an additional 1,426,184 shares in the last quarter. Van ECK Associates Corp lifted its position in shares of Takeda Pharmaceutical by 98.4% in the 4th quarter. Van ECK Associates Corp now owns 2,305,397 shares of the company’s stock valued at $35,941,000 after acquiring an additional 1,143,117 shares in the last quarter. Finally, Voloridge Investment Management LLC lifted its position in shares of Takeda Pharmaceutical by 1,070.7% in the 4th quarter. Voloridge Investment Management LLC now owns 962,502 shares of the company’s stock valued at $15,005,000 after acquiring an additional 880,289 shares in the last quarter. 9.17% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on TAK shares. Sanford C. Bernstein upgraded shares of Takeda Pharmaceutical from a “market perform” rating to an “outperform” rating in a research note on Wednesday, April 8th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Takeda Pharmaceutical in a research report on Wednesday, April 29th. Zacks Research raised shares of Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 3rd. Finally, Wall Street Zen raised shares of Takeda Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research report on Saturday, April 11th. Two research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy”.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.